Lawsuit Alert: Investors who lost money with shares of Avantor, Inc. (NYSE: AVTR) should contact the Shareholders Foundation

An investor, who purchased shares of Avantor, Inc. (NYSE: AVTR), filed a lawsuit over alleged violations of Federal Securities Laws by Avantor, Inc. in connection with certain allegedly false and misleading statements.

Investors who purchased shares of Avantor, Inc. (NYSE: AVTR) have certain options and for certain investors are short and strict deadlines running. Deadline: December 29, 2025. NYSE: AVTR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Radnor, PA based Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. Avantor, Inc. (NYSE: AVTR) reported that its annual Total Revenue declined from over $6.96 billion in 2023 to $6.78 billion in 2024 and that its Net Income increased from $321.1 million in 2023 to $711.5 million in 2024.

On March 5, 2024, Michael Stubblefield, then the Company's President and Chief Executive Officer, represented Avantor, Inc. at a TD Cowen healthcare industry conference. In response to an analyst's question about Avantor's competitive positioning in its Laboratory Solutions business, Stubblefield emphasized that Avantor's competitive position "[c]ontinues to be strong," further representing that "we continue to have confidence in the positioning [of] a lot of investments in our digital capabilities there to make it more efficient for our customers to engage with us..." and that "the traffic to our sites relative to our competitors is a nice indicator for our business."

On July 26, 2024 during an earnings call, in response to an analyst's question about whether Avantor was losing share to a competitor, Michael Stubblefield, then the Company's President and Chief Executive Officer, assured investors that Avantor's "lab business stacks up well against every number that certainly that we've seen," that "we continue to enhance our position," and that "we're really confident in our value proposition and our competitive position." Likewise, Avantor, Inc repeatedly pointed to Avantor's purported competitive advantages, such as its digital capabilities, as evidence that the Company would continue to enjoy strong competitive positioning.

On April 25, 2025, Avantor, Inc reported its first quarter 2025 financial results, cut its guidance for 2025, and announced that Michael Stubblefield would be stepping down from his roles as President and Chief Executive Officer. Avantor, Inc attributed Avantor's weak performance and outlook to "the impact of increased competitive intensity."

Then, on August 1, 2025, Avantor, Inc reported second quarter 2025 financial results, including a year-over-year decrease in net sales, and further reduced the Company's 2025 guidance-now projecting organic revenue growth of -2% to 0%. Avantor, Inc again attributed Avantor's poor results and outlook to "increased competitive intensity," and further admitted that the Company did not expect the competitive environment to materially improve in the remainder of 2025 and weak performance would therefore likely persist.

Finally, on October 29, 2025, Avantor, Inc reported third quarter 2025 financial results, including -5% organic revenue growth (below the guidance Defendants had provided in August), and a net loss of $712 million, which Avantor, Inc primarily attributed to a non-cash goodwill impairment charge of $785 million. Defendants revealed that the impairment charge was necessary due in part to "competitive pressures" that had "meaningfully impacted" the Company's margins, and further admitted that the Company had lost several large contracts.

Shares of Avantor, Inc. (NYSE: AVTR) declined from $28.00 per share on July 31, 2024, to $10.82 per share on October 31, 2025.

The plaintiff claims that between March 5, 2024, and October 28, 2025, the defendants misrepresented and/or failed to disclose that Avantor's competitive positioning was weaker than Defendants had publicly represented, that Avantor was experiencing negative effects from increased competition, and that as a result, Defendants' representations about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.

Those who purchased shares of Avantor, Inc. (NYSE: AVTR) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.